Proteomics International Laboratories (ASX:PIQ) formed its clinical advisory board for PromarkerEso, a diagnostic blood test for esophageal cancer, according to a Monday filing with the Australian bourse.
The advisory board will provide guidance and clinical insights for the global commercialization of PromarkerEso, the filing said.
The company is set to launch PromarkerEso in Australia, with other jurisdictions expected to follow, per the filing.
Shares fell 8% in recent trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.